Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

05-07-2019

Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

hafakot / Shutterstock.com

US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.


Genentech, Samsung Bioepis, patent infringement, trastuzumab, Herceptin, Ontruzant, biosimilar

LSIPR